Benchmark

OncoVI 2026 oncogenicity evaluation study

Published-study grouping of the catalogued evaluation protocols. This grouping does not claim an executable suite, full-paper extraction or independent clinical validation.

5 evaluations · 27 results

Overview

Published-study grouping of the catalogued evaluation protocols. This grouping does not claim an executable suite, full-paper extraction or independent clinical validation.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

5 recorded evaluations, 27 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

5 evaluations · 27 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	83% accuracy percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	81.1% missense_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, missense_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	76.1% oncogene_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, oncogene_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	84% oncogenic_sensitivity percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, oncogenic_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	87.5% truncating_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, truncating_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	85.7% tsg_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, tsg_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	80% expert_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, expert_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	22% prior_mtb_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, prior_mtb_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	0.7 score_correlation correlation coefficient · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 4C, concordant variants only
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	43% benign_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	78% concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	78.2% missense_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	82.5% oncogene_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	79% oncogenic_vs_pathogenic_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	49.4% truncating_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	76% tsg_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	97% vus_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6
Configuration: Historical Erlangen MTB protein-function interpretation	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	34% expert_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Historical MTB agreement with expert oncogenicity reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A
Configuration: Historical Erlangen MTB protein-function interpretation	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	46 expert_concordant_variants count · unknown Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source Historical MTB agreement with expert oncogenicity reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, validation data set, paragraph ending 46/135; Figure 4A
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	81% accuracy percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	83% benign_sensitivity percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, benign_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	83.1% missense_accuracy percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, missense_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	82% oncogene_accuracy percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, oncogene_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	88% oncogenic_sensitivity percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, oncogenic_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	0.87 score_correlation correlation coefficient · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 2B, concordant variants only

Source checking is not independent reproduction. Release 2026-09-30-e37e3ab1284d.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Evaluation design

Benchmarks bring together tasks and protocols. A task describes the biological question; a protocol defines a particular test.

Protocols

These source-backed links do not make different protocols or scores interchangeable.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 8 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

Baseline status by linked protocol

OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions · 0/2 roles measured
OncoVI three-class assessment: MTB selected expert reassessment · 0/2 roles measured
OncoVI three-class assessment: Erlangen MTB variants · 0/2 roles measured
OncoVI three-class assessment: Guideline SOP variants · 0/2 roles measured

Protocol coverage CSV · Model evaluation matrix · Source table · Release and checksums

Coverage is derived from release 2026-09-30-e37e3ab1284d. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run this benchmark

Choose a concrete protocol before running an evaluation. Its inputs, split and scoring rules determine which results can be compared.

Run instructions

No runnable recipe has been reviewed for this benchmark. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-09-30-e37e3ab1284d
Property and statement	Original source and location	Review and provenance

No evidence rows match these filters. Choose another scope or clear the search.

All evidence (CSV)All evidence (JSONL)How to read the evidence

Sources and history

View linked audit checks and correction history

Release 2026-09-30-e37e3ab1284d · Record review: source checked

1 source records and release history

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Original source · 2026 final full text in Europe PMC XML

Download this release

Technical metadata and extraction receipts

Stable ID: uc-clinical-20260930-benchmark-oncovi-study

areas: dna-genomes
contexts: clinical_research
entity level: suite
grouping type: published_study_evaluations
executable suite: false
source locator: Results and Figures2–4; ClinVar assessment
review: method: automated_source_review; reviewer: Codex clinical coverage worker; date: 2026-09-30; note: Transcription from inspected primary source. No execution, independent replication or human scientific review.; source id: uc-clinical-20260930-source-oncovi

Related records

Suggest a correction